Company: REVB
Filing Date: 2025-05-20
Form Type: S-1
Source: 0001213900-25-045828
Chunk: 94

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-20
Form: S-1
Chunk 94
---
 options and third-party warrants are generally determined using the Black-Scholes option-pricing model using various inputs, including estimates of historic volatility, term, risk-free rate, and future dividends. The grant date fair value of the stock-based awards, which have graded vesting, is recognized using the straight-line method over the requisite service period of each stock-based award, which is generally the vesting period of the respective stock-based awards. The Company recognizes forfeitures as they occur. Recent Accounting Pronouncements See Note 2 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report for the quarterly period ending March 31, 2025 for more information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one yet, of their potential impact on our financial condition of results of operations. 54 DESCRIPTION OF THE COMPANY’S BUSINESS Throughout this section, unless otherwise noted, “we,” “us,” “our,” “Revelation” and the “Company” refer to Revelation Biosciences, Inc. and its subsidiary. Overview Revelation is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We have multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention for acute kidney injury, GEM-CKD as a treatment for chronic kidney disease, GEM-PSI as a prevention for post surgical infection and GEM-PBI as a prevention of infection in severe burn patients requiring hospitalization. The Company was incorporated in the state of Delaware on November 20, 2019 (originally as Petra Acquisition, Inc.) and is based in San Diego, California. Our common stock and warrants sold in our initial public offering (“Public Warrants”) are listed on The Nasdaq Stock Market, LLC (“Nasdaq”) under the ticker symbol “REVB” and “REVBW,” respectively. Recent Developments 2025 Reverse Stock Split On January 17, 2025, at a special meeting of stockholders, our stockholders approved a Certificate of Amendment to our Third Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding shares of common stock at a specific ratio within a range of one-for-two (1-for-2) to a maximum of a one-for-fifty (1-for-50) split. Following the special meeting of stockholders and determination by the Board